期刊文献+

白蛋白结合型紫杉醇对人骨肉瘤OS-732细胞的体外抑制作用观察 被引量:10

In vitro inhibiting effect of albumin-bound paclitaxel on human osteosarcoma cell OS-732
下载PDF
导出
摘要 目的观察白蛋白结合型紫杉醇(Abraxane)对人骨肉瘤OS-732细胞的体外抑制作用。方法取传代第3天、处于指数增殖期的人骨肉瘤OS-732细胞,分别加入不同浓度的阿霉素、紫杉醇(泰素)和Abraxane培养,于培养24、72、144 h时用MTT法测定细胞的光密度值(OD值)并计算细胞毒性指数(CI),倒置相差显微镜观察细胞形态,流式细胞术检测细胞周期。结果骨肉瘤OS-732细胞加入Abraxane后,OD值下降,以加入100、1 000μg/ml的Abraxane组及培养72、144 h时下降明显,CI则相应升高,同时细胞变小、核碎裂,G2~M期细胞的比例逐渐增加;除100μg/ml浓度处理24 h和72 h后,泰素处理组的CI高于Abraxane组外,两组相同浓度、相同处理时间的CI相近;最高剂量Abraxane和最高剂量阿霉素组的CI也相近。结论 Abraxane在体外对骨肉瘤OS-732细胞有显著的抑制作用,能将骨肉瘤细胞阻滞于G2~M期。Abraxane与泰素和阿霉素的细胞毒性相似。 Objective To evaluate the inhibiting effect of albumin-bound paclitaxel(Abraxane) on human osteosarcoma cell OS-732 in vitro.Methods human osteosarcoma OS-732 cells were cultured for 3 days in proliferation period.Adriamycin,paclitaxel(Taxol) and Abraxane were used to treat osteosarcoma cells for 24 h,72 h and 144 h.MTT was used to evaluate the cytotoxic effects through measuring optical density(OD) and cytotoxity index(CI).Cellular morphologic changes were observed with phase contrast microscope.FCM was performed to detect cell cycle phase and DNA ploidy in osteosarcoma cells.Results The OD of cells treated by 100 μg/ml and 1 000 μg/ml Abraxane descended significantly over time,and the CI value elevated as well,while cells shrinked and nuclear chipped.With the increasing of drug concentration,G2~M phase cells increased gradually.The osteosarcoma cells received Abraxane showed similar CI with that in Taxol group,except that cells treated by 100 μg/ml concentration for 24 h and 72 h.The CI in maxium concentration Abraxane group was similar with that in maxium concentration Adriamycin group.Conclusions Abraxane has anti-tumor activity in human osteosarcoma cell OS-732 in vitro.The cells showe G2 ~ M cell cycle arrest after treatment.The cytotoxity of Abraxane is similar with Adriamycin and Taxol.
出处 《山东医药》 CAS 北大核心 2010年第42期24-26,共3页 Shandong Medical Journal
关键词 紫杉醇 结核型紫杉醇 骨肿瘤 骨肉瘤细胞 化学疗法 细胞增殖 细胞毒性 细胞凋亡 paclitaxel albumin-bound paclitaxel bone tumor osteosarcoma cells chemotherapy cell proliferation cytotoxicity apoptosis
  • 相关文献

参考文献8

  • 1Lu KH,Lue KH,Chou MC,et al.Paclitaxel induces apoptosis via caspase-3 activation in human osteogenic sarcoma cells (U-2 OS)[J].J Orth Res,2005,23(5):988-994.
  • 2Guan ZZ,Li QL,Feng FY,et al.Superior efficacy of a Cremophor-free albumin-bound paclitaxel compared with solvent-based paclitaxel in Chinese patients with metastatic breast cancer[J].Asia Pac J Clin Oncol,2009,5(3):159-174.
  • 3Tiruppathi C,Finnegan A,Malik AB.Isolation and characterization of a cell surface albumin-binding protein from vascular endothelial cells[J].Proc Natl Acad Sci USA,1996,93(1):250-254.
  • 4Bacci G,Longhi A,Fagioli F,et al.Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities:27 year experience at Rizzoli Institute,Italy[J].Eur J Cancer,2005,41(18):2836-2845.
  • 5牛晓辉,蔡槱伯,张清,郝林,丁易.ⅡB期肢体骨肉瘤189例综合治疗临床分析[J].中华外科杂志,2005,43(24):1576-1579. 被引量:41
  • 6Guo W,Zeng C,Dong FQ,et al.Paclitaxel-induced apoptosis in osteosarcoma cell line U-2 OS[J].Chin Med J(Engl),2002,115(12):1796-1801.
  • 7Mankin HJ,Fondren G,Horricek FJ,et al.The use of flow cytometry in assessing malignancy in bone and soft tissue tumors[J].Clin Orthop Relat Res,2002,(397):95-105.
  • 8Lu K,Wang D,Lue K,et al.PCR and flow cytometric analysis of paclitaxel-inhibited arylamine N-acetyltransferase activity and gene expression in human osteogenic sarcoma cells (U-2 OS)[J].Anticancer Res,2004,24(1):83-90.

二级参考文献4

  • 1Enneking WF,Spanier SS,Goodman MA.A system for the surgical staging of musculoskeletal sarcoma.Clin Orthop,1980,(153):106-120.
  • 2Enneking WF,Dunham W,Gebhardt MC.A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system.Clin Orthop,1993,(286):241-248.
  • 3Bacci G,Forni C,Ferrari S.Neoadjuvant chemotherapy for osteosarcoma of the extremity:intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome.J Pediatr Hematol Oncol,2003,25:845-853.
  • 4蔡槱伯,牛晓辉,张清,郝林,刘文生,鱼锋.肢体原发成骨肉瘤综合治疗的远期结果[J].中华外科杂志,2000,38(5):329-331. 被引量:34

共引文献40

同被引文献90

  • 1董岿然,高解春,肖现民.小儿常见恶性实体肿瘤耐药性分析[J].临床小儿外科杂志,2002,1(1):33-35. 被引量:3
  • 2王振义,孙关林,陈竺.诱导分化疗法应用的现状[J].中华血液学杂志,1994,15(2):105-107. 被引量:28
  • 3杨彤涛,牛子长,李存孝,黄立军,高杰,马保安,范清宇,周勇.表没食子儿茶素-3-没食子酸酯抑制骨肉瘤细胞增殖及其机制[J].实用医学杂志,2007,23(10):1449-1451. 被引量:7
  • 4陶海,蔡林.多西紫杉醇联合顺铂在人骨肉瘤化疗中的作用[J].中国矫形外科杂志,2007,15(11):856-859. 被引量:2
  • 5Bay JO,Cahrespine A,Gilliot O,et al.Docetaxel and gemcitabine combination in soft-tissue sarcomas treatment[J].Bull Cancer,2007,94:S122-126.
  • 6Penel N,Van Glabbeke M,Marreaud S,et al.Testing new regimens in patients with advanced soft tissue.sarcoma:analysis of publications from the last 10 years.Ann Oncol,2011,22 (6):1266-1272.
  • 7Saylors RL 3rd,Stine KC,Sullivan J,et al.Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors:a Pe diatric Oncology Group phase Ⅱ study[J].J Clin Oncol,2001,19 (15):3463-3469.
  • 8Kleinerman ES,Gano JB,Johnston DA,et al.Efficacy of liposomal muramyl tripcptide (CGP 19835A) in the treament of relapsed osteosarcoma[J].Am J Clin Oncol,1995,18(2):93-99.
  • 9Kersting C,Gebert C,Agelopoulos K,et al.Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome[J].Clin Cancer Res,2007,13 (10):2998-3005.
  • 10Carter SR,Grimer RJ,Sheath RS,et al.Results of thoracotomy in osteogeni sarcoma with pulmonary metastases[J].Thorax,1991,46(10):727-731.

引证文献10

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部